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Introduction
The ultimate goal of this project is to develop specific PET imaging probes for early detection of distal metastases of prostate cancer. Based on one of our studies using a polyarginine (NH 2 GR11) to deliver a therapeutic moiety to various prostate cancer cell lines, we hypothesize a new group of prostate-specific peptides could be developed as novel PET imaging probes using NH 2 GR11 as lead compound for the detection of multi-foci extraprostatic spread of prostate cancer. Three specific aims are arranged to achieve the goals of this proposal: (I) Determine the mechanism of the prostate-specific uptake exhibited by NH 2 GR11; (II) Design and synthesize novel BFC-peptide conjugates in order to achieve desired in vivo stability, pharmacokinetics, and enhanced prostate-specific binding affinity; and (III) Establish radiochemical protocols to label peptide conjugates with 64 Cu, and perform in vitro/in vivo evaluations of the potential prostate cancer-specific imaging agents.
Body
As shown in the first annual report, we completed the tasks 1 -5 in the first year of this project. In the 2 nd year, our work was focused on the following tasks:
Task 5 (Months 6 -12): Establishing radiochemical protocols to label the peptide conjugates with 64 Cu. Radiolabeling of the peptide conjugates with 64 Cu is straightforward, the separation and purification will be carried out by either C-18 cartridge or HPLC.
Task 6 (Months 12 -24): In Vitro Evaluation of the Radiolabeled Peptides.
The in vitro stability of the radiolabeled peptides or peptide conjugates will be determined by incubation at 37 o C in fresh mammalian serum out to 24 h. Degradation of the radiolabeled compounds will be assessed at given time points (30-min, 1-h, 4-h, and 24-h) by the removal of an aliquot of sample for radio-TLC (C 18 or silica gel solid phase) or radio-HPLC (C 18 and size-exclusion column) analysis.
The in vitro stability of the 64 Cu labeled peptide conjugates was evaluated in rat serum by radio-HPLC. Chromatographic results showed no release of 64 Cu from the conjugates over a period of 48 h. This high stability is rendered by the CB-TE2A moiety in the conjugates.
Cell Integrin Receptor-Binding Assay:
The α υ β 3 integrin-binding affinities of 64 Cu-1 and 64 Cu-2. were determined by a competitive cell-binding assay using 125 I-echistatin (PerkinElmer) as the α υ β 3 -specific radioligand. The experiments were performed on U87MG human glioblastoma cells by a previously reported method (1, 2) . Briefly, U87MG cells were grown in Dulbecco's modified Eagle medium (DMEM, low glucose) supplemented with 10% (v/v) fetal bovine serum (FBS) at 37ºC with 5% CO 2 . Suspended U87MG cells in binding buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCl 2 , 0.1% bovine serum albumin) were seeded on multi-screen DV plates (Millipore) with 2 × 10 5 cells per well and then incubated with 125 I-echistatin (10,000 cpm/well) in the presence of increasing concentrations (0 -5,000 nM) of c(RGDyK) peptide conjugates for 2 h. The final volume in each well was maintained at 200 μL. At the end of incubation, the unbound 125 I-echistatin was removed by filtration and then three times of rinsing with cold binding buffer. The filters were collected and the radioactivity was measured using a γ-counter. The best-fit IC 50 values (inhibitory concentration where 50% of the 125 I-echistatin bound on U87MG cells are displaced) of c(RGDyK), H 2 1, and H 2 2 were calculated by fitting the data with nonlinear regression using GraphPad Prism (GraphPad Software, Inc.) . Experiments were duplicated with quintuplicate samples. The results are shown in Figure 1 . 
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Normalized % bound 12 5 I-echistatin Figure 1 . The α υ β 3 binding affinities of H 2 1 and H 2 2 measured by a competitive cell-binding assay using U87MG cells where 125 I-echistation was employed as α υ β 3 -specific radioligand. The IC 50 values of c(RGDyK), H 2 1, and H 2 2, were determined to be 110, 139 and 35 nM, respectively (n = 5).
The α υ β 3 binding affinities of H 2 1 and H 2 2 were measured by a competitive cell-binding assay using U87MG cells where 125 I-echistation was employed as α υ β 3 -specific radioligand for the competitive displacement. (3) The IC 50 values of c(RGDyK), H 2 1, and H 2 2, which represent their concentrations required to displace 50% of the 125 I-echistation bound on the U87MG cells, were determined to be 110, 139 and 35 nM, respectively (n = 5). The slightly decreased α υ β 3 binding of H 2 1 as compared to c(RGDyK) indicates a minute impact of CB-TE2A on the binding of c(RGDyK) to the α υ β 3 integrin. As anticipated, H 2 2 exhibited a strong divalent effect measured by the multivalent enhancement ratio (MVE) calculated by dividing the IC 50 value of H 2 1 by that of H 2 2 (MVE = 4). (4) The distance between the two RGD motifs in H 2 2 is maintained greater than 25 bonds (including the lysine spacers), the minimum spacing length required to realize multivalent binding of RGD motifs to the α υ β 3 integrin.(3)
Task 7 (Months 12 -32): In Vivo Evaluation of Radiolabeled Peptides

I. Using c(RGDyK) as a model peptide to validate the multimeric imaging probe design
Tissue Culture and Animal Model: All animal studies were performed in compliance with guidelines set by the UT Southwestern Institutional Animal Care and Use Committee. The PC-3 cell line was obtained from the American Type Culture Collection (ATCC, Manassas, VA). PC-3 cells were cultured in T-media (Invitrogen, Carlsbad, CA) at 37
• C in an atmosphere of 5% CO 2 and were passaged at 75 % confluence in P150 plates. T-media was supplemented with 5% Fetal Bovine Serum (FBS) and 1 × Penicillin/Streptomycin. PC-3 cells were harvested from monolayer using PBS and trypsin/EDTA, and suspended in T-media with 5% FBS. The cell suspension was then mixed 1:1 with Matrigel™ and injected subcutaneously (2.5 × 10 6 cells per injection, injection volume 100 µL) into both front flanks of SCID mice. After injection, animals were monitored three times a week by general observations. The tumor was noticed to grow in the first week and allowed to grow three weeks to reach a palpable size for microPET-CT imaging and post-PET biodistribution studies. Tumor volume (mm 3 ) was calculated using the ellipsoid formula (π/6 × length × width × depth).
MicroPET-CT Imaging: Small animal PET-CT imaging studies were performed on a Siemens Inveon PET-CT Multimodality System (Siemens Medical Solutions Inc., Knoxville, TN, USA). When the prostate cancer xenografts reached the similar size of approximate 100 mm 3 , the tumor-bearing mice were randomized into four groups (n = 3) for the in vivo evaluation of 64 Cu-1, 64 Cu-2, 64 Cu-1 with co-injection of c(RGDyK), and 64 Cu-2 with co-injection of c(RGDyK). The dose of c(RGDyK) used for blocking was 10 mg/kg. The injected dose was kept at 100 μCi of 64 Cu-activity in 100 μL PBS; and the injected molar amounts of 64 Cu-2 were maintained at the same level by decay correction. Ten minutes prior to imaging, the animal was anesthetized using 3% Isofluorane at room temperature until stable vitals were established. Once the animal was sedated, the animal was placed onto the imaging bed under 2% Isofluorane anesthesia for the duration of the imaging. The microCT imaging was acquired at 80 kV and 500 μA with a focal spot of 58 μm. The total rotation of the gantry was 360 o with 360 rotation steps obtained at an exposure time of approximately 235 ms/frame. The images were attained using a CCD readout of 4096 × 3098 with a bin factor of 4 and an average frame of 1. Under low magnification the effective pixel size was 103.03 μm. Total microCT scan time was approximately 6 minutes. CT images were reconstructed with a down sample factor of 2 using Cobra Reconstruction Software. The PET imaging was acquired directly following the acquisition of CT data. The PET tracers were injected intravenously via the tail vein. Static PET scans were performed at 1 h, 4 h, and 24 h post injection (p. The tissues examined include the left and right tumors, the heart, liver, lung, kidney, and muscle. The resulting quantitative data was expressed as percent injected dose per gram of tissue (%ID/g).
Six SCID mice (6 -7 weeks old) bearing PC-3 human prostate cancer xenografts in both front flanks (tumor size: ~ 230 mg) were randomized into two groups (n = 3) for the evaluation of 64 Cu-1 or 64 Cu-2, which was injected via the tail-vein. As shown in Figure 2 Tables 1 -3 Post-PET Biodistribution: Immediately after the 24 h imaging, the mice were sacrificed and organs of interest were removed, weighed, and counted by a γ-counter. Standards were prepared and counted along with the samples to calculate the percent injected dose per gram (%ID/g) and percent injected dose per organ (%ID/organ). These data suggest that the significantly greater uptake and prolonged signal intensity of 64 Cu-2 in tumor reflects the advantages of the scaffolding design of H 2 2, which affords optimal in vivo kinetics in addition to the anticipated multivalent effects. It must be pointed out that there are two chiral centers in the pendent arms of Cu-2, which can statistically give rise to three diastereomers (R/R, S/S, and a meso R/S), although they, if existing, are spectrally indistinguishable in this work. While the purpose of this work is to demonstrate the feasibility of our concept that multivalent imaging probes can be constructed on a bifunctional chelator, an enantiopure isomer should be considered for future clinical applications of this type of multivalent scaffolds. Used as a sample targeting molecule in this work, c(RGDyK) can be obviously replaced by other targeting peptides or small organic molecules for imaging of various diseases or non-invasive cell surface receptor mapping. In summary, we have demonstrated a divalent scaffolding design for targeted imaging probe development. Obviously this concept can be applied to the design of other multivalent scaffolds based on NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) .
II. Using an arginine-rich cell-permeable peptide (NH 2 GR 11 ) to target prostate cancer
Chemical reagents and instrument
All chemicals were of reagent grade and used as received unless otherwise noted. FITC-NHGR 9 , FITC-NHGR 11 , FITC-NHGR 13 , and DOTA-NHGR 11 (DOTA: 1, 4, 7, 4, 7, were synthesized by the Peptide Synthesis Laboratory of the University of Texas Southwestern Medical Center (Dallas, TX). Copper-64 chloride in 0.1N HCl was purchased from the University of Wisconsin-Madison. Milli-Q water (18 MΩ-cm) was obtained from a Millipore Gradient Milli-Q water system (Billerica, MA). All aqueous solutions were prepared with Milli-Q water. Light C-18 Sep-Pak cartridges were purchased from Waters (Milford, MA). Instant thin-layer chromatography (ITLC-SG) plates were purchased from Pall Life Sciences (East Hills, NY).
MALDI-TOF mass spectra were collected on a Voyager-DE™ PRO Biospectrometry Workstation (Applied Biosystems, Foster City, CA). Small animal PET-CT imaging studies were performed on a Siemens Inveon PET-CT Multimodality System (Siemens Medical Solutions Inc., Knoxville, TN).
Cell culture and animal models
All the cell lines used in this work (LNCaP, PZ-HPV-7, DU145, PC3, and H2009) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Both LNCaP and PC3 cell lines were cultured in T-media (Invitrogen Corporation, Carlsbad, CA) supplemented with 5% FBS and 1× Penicillin/Streptomycin. PZ-HPV-7 (an immortalized normal prostate epithelial cell line) and DU145 cell lines were maintained in PrEGM medium (Lonza, Walkersville, MD) and RPMI1640 medium (ThermoFisher Scientific, US) supplemented with 10% FBS and 1× Penicillin/Streptomycin, respectively. The H2009, a non-small lung cancer, cell line was cultured in RPMI1640 medium supplemented with 5% FBS. All the cell lines were cultured at 37 °C in an atmosphere of 5% CO 2 and passaged at 75 % confluence.
All animal studies were performed in compliance with guidelines set by the UT Southwestern Institutional Animal Care and Use Committee. Male nu/nu nude mice (5 -7 weeks of age) were purchased from Harlan (Indianapolis, IN), and male SCID mice (6 -8 weeks of age) were purchased from the UT Southwestern mouse-breeding core (Wakeland Colony). To establish the PC3 tumor xenograft mouse model, PC3 cell suspension was mixed 1:1 with Matrigel (BD Biosciences, Bedford, MA) and then injected subcutaneously (2 × 10 6 cells per site, injection volume 100 µL) into both flanks of animals. For the H2009 tumor model, the cell suspension was injected subcutaneously (1 × 10 6 cells per site, injection volume 100 µL) into the back of both shoulders of SCID mice. After injection, the animals were monitored three times a week by general observations. Small PET-CT imaging was performed when the tumors become palpable.
In vitro cell uptake and subcellular localization
To determine the uptake efficiency of CPPs, 1 × 10 4 cells per well were seeded in 12-well plates and allowed to grow for 24 h. Then a FITC-tagged CCP (5 M) was added and incubated with cells for 30 min. After removal of the medium, the cells were treated with Tryphan Blue (0.4% w/v, Mediatech, Inc., Herndon, VA) to quench the extracellular fluorescence and washed three times with cold PBS. The cells were then lysed with Tris Buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X100). The fluorescence intensity was measured by SpectraMax M5 (Molecular Devices, Sunnyvale, CA) with an excitation wavelength of 490 nm, an emission wavelength of 530 nm, and a cutoff wavelength of 515 nm. The protein concentration in each well was determined using a BCA protein assay kit (Pierce, Rockford, IL). The uptake efficiency of each CPP was determined by normalizing the fluorescence intensity with the protein concentration and the relative uptake was calculated as compared to that of FITC-NHGR 11 . To determine the subcellular localization of a CPP, after 30 min incubation, the cells were fixed with 4% paraformaldehyde in PBS buffer and then counterstained with 1 µg/mL DAPI (Sigma, St. Louis, MO). Each sample was examined under a fluorescence microscope.
The oligoarginine length effect on the cell uptake efficiency was evaluated using FITC-NHGR 9 , FITC-NHGR 11 and FITC-NHGR 13 in four different human prostate cell lines: PZ-HPV-7, LNCaP, PC3, and DU145. For comparison, the uptake of FITC-NHGR 11 is set at 1.0. As shown in Figure 3a , after 30 min incubation, FITC-NHGR 11 displayed much higher uptake efficiency than FITC-NHGR 9 and FITC-NHGR 13 (p < 0.005) in all the four cell lines indicating that the intracellular uptake of oligoarginines is greatly affected by the number of the repeating guanidino moiety. Of the three FITC-tagged oligoarginines, FITC-NHGR 13 showed the lowest uptake in three of the tested cell lines (PZ-HPV-7, PC3, and DU145). In PC3 and DU145, FITC-NHGR 9 displayed appreciable uptake values, which are 63% and 65% of that of FITC-NHGR 11 , respectively. Overall, the PZ-HPV-7 and LNCaP cell lines exhibited highly selective internalization of oligoarginines varying with the peptide length.
The subcellular localization of FITC-NHGR 9 , FITC-NHGR 11 and FITC-NHGR 13 in the prostate cancer cell lines was shown in Figure 3b . Apparently, FITC-NHGR 11 exhibited a higher fluorescent intensity in all the cell lines. The majority of FITC-NHGR 11 was localized in the cytosol, while in PZ-HPV-7 and PC3 cell lines, nuclear staining with FITC-NHGR 11 was also seen. Both FITC-NHGR 9 and FITC-NHGR 13 showed significantly lower fluorescent intensity than FITC-NHGR 11 in all four tested cell lines, which is consistent with the cell uptake results. Taken together, these data demonstrate the high efficiency and amino acid length-dependent uptake of FITC-NHGR 11 in various prostate cell lines, which has made FITC-NHGR 11 as a unique probe for detecting prostate cancer. 
Preparation of
64 Cu-DOTA-NHGR 11 To a 1.5 mL vial containing 10 μg DOTA-NHGR 11 in 200 µL of 0.4 M NH 4 OAc solution (pH = 6.5), 2 -3 mCi of 64 Cu in 0.1 M HCl was added. The reaction mixture was vortexed and then incubated at 37 ºC. After 30-min incubation, 5 µL of 5 mM diethylenetriaminepentaacetic acid (DTPA) was added and the reaction mixture was incubated at room temperature for 5 min. The separation of 64 Cu-DOTA-NHGR 11 from 64 Cu-DTPA was carried out by passing the reaction mixture through a light C-18 Sep-Pak cartridge. After three times of washings with PBS, the product was eluted with 80% ethanol solution. Radio-TLC analysis was performed on a Rita Star Radioisotope TLC Analyzer (Straubenhardt, Germany) to monitor the radiolabeling reaction using ITLC paper as the plate and 10 mM PBS as the mobile phase. High performance liquid chromatography (HPLC) analysis was conducted to determine the radiochemical purity of the products using a Waters 600 Multisolvent Delivery System equipped with a Waters 2996 Photodiode Array (PDA) detector and an in-line Shell Jr. The conjugate, DOTA-NHGR 11 , was labeled with 64 Cu by incubating with 64 Cu 2+ in 0.4 M NH 4 OAc buffer (pH = 6.5) at 37 ºC for 30 min. Nonspecifically bound 64 Cu was removed in the form of 64 Cu-DTPA at the end of the radiolabling procedure. The radiolabeling reaction was monitored by radio-TLC analysis, in which the reaction mixture was sampled on an instant TLC plate that was then developed in PBS buffer. Under the TLC conditions, 64 Cu-DOTA-NHGR 11 stayed at the origin, while 64
Cu-DTPA moved to the solvent front. The radiochemical yield was > 90% when 10 μg of the DOTA conjugate was used to label 2 -3 mCi of 64 Cu. The 64 Cu-DTPA was removed by passing the reaction mixture through a light C18 SepPak cartridge and three times of washing with PBS. The product, 64 Cu-DOTA-NHGR 11, could then be efficiently eluted with 80% of ethanol. The radiochemical purity of 64 Cu-DOTA-NHGR 11 was nearly 100% after the Sep-Pak purification as determined by radio-ITLC and radio-HPLC. To confirm the identity of the labeled product, nat Cu-DOTA-NHGR 11 was prepared and used as a reference standard. Both 64 Cu-DOTA-NHGR 11 and nat Cu-DOTA-NHGR 11 showed a single peak on HPLC ( 64 Cu-DOTA-NHGR 11 : radioactivity detector; nat Cu-DOTA-NHGR 11 : PDA UV detector) with the same retention time within 14 -15 min.
Small Animal PET/CT Imaging
When the tumor size reached the range of 50 -300 mm 3 , the tumor-bearing mice were randomized for the PET-CT imaging with 64 Cu-DOTA-NHGR 11 . The injected dose was 3.7 MBq of 64 Cu-activity in 100 μL of PBS, while the injected molar amount of NH 2 GR 11 was maintained at the same level by decay correction. Ten minutes prior to imaging, the animal was anesthetized using 3% isofluorane at room temperature until stable vitals were established. Once the animal was sedated, it was placed onto the imaging bed under 2% isofluorane anesthesia for the duration of the imaging. The CT imaging was acquired at 80 kV and 500 μA with a focal spot of 58 μm. The total rotation of the gantry was 360° with 360 rotation steps obtained at an exposure time of approximately 235 ms/frame. The images were attained using a CCD readout of 4096 × 3098 with a bin factor of 4 and an average frame of 1. Under low magnification the effective pixel size was 103.03 μm. Total CT scan time was approximately 6 minutes. CT images were reconstructed with a down sample factor of 2 using Cobra Reconstruction Software. The PET imaging was performed directly after the acquisition of CT data. The PET tracer was injected intravenously via the tail vein. Static PET scans were performed at 1 h, 4 h, and 24 h p.i. for 15 min. PET images at 1 h and 4 h p.i. were reconstructed using Fourier Rebinning and Ordered Subsets Expectation Maximization 3D (OSEM3D) algorithm, while the PET images at 24 h p.i. were reconstructed using OSEM2D. Reconstructed CT and PET images were fused and analyzed using the Siemens Inveon Research Workplace (IRW) software. For quantification, regions of interest were placed in the areas expressing the highest radiotracer activity as determined by visual inspection. The tissues examined include the left and right tumors, heart, liver, lung, kidneys, and muscle. The resulting quantitative data was expressed as percent injected dose per gram of tissue (%ID/g). Statistical Analysis: Quantitative data were expressed as Mean ± SD and then compared using one-way analysis of variance and Student's t test. P values < 0.05 were considered statistically significant.
The comparative small animal imaging evaluation of 64 Cu-DOTA-NHGR 11 was performed using PC3 and H2009 tumor-bearing SCID mice, which were injected with a similar amount of peptide with respect to the volume of tumor as calculated based on the specificity radioactivity of 64 Cu-DOTA-NHGR 11 . The PET-CT imaging acquisition was conducted at 1, 4, and 24 h p.i. (n = 3 at each time point). The representative PET-CT images (transaxial) are presented in Fig 4. Due to the low counts at 24 h p.i. resulted from the clearance and decay of the radiotracer, the PET images at 24 h p.i. were reconstructed by the OSEM2D algorithm instead of OSEM3D that was applied to process the 1 h and 4 h images. As shown in Fig 4 , the PC3 tumors on both flanks were clearly visualized by 64 Cu-DOTA-NHGR 11 on PET images at 1 h and 4 h p.i. At 24 h p.i., the PC3 tumors became faint on PET but still with a significant level of signals. In contrast, the H2009 tumors were only visible at 1 h with much lower signal intensity on PET as compared to the PC3 tumors; at 4 h and 24 h p.i., they became not detectable.
The PET images were quantitatively analyzed by the Siemens Inveon Research Workplace (IRW) software. Summarized in Table 4 Cu-DOTA-NHGR 11 in PC3 tumor versus muscle at 1 h, 4 h, and 24 h p.i. were 5.06 ± 0.96, 4.87 ± 1.29, and 10.41 ± 6.07, respectively. In other organs, 64 Cu-DOTA-NHGR 11 exhibited a very similar distribution pattern in both tumor-bearing mouse models. With the goal to develop NH 2 GR 11 for specific PET imaging of prostate cancer metastases, we designed and performed a comparative PET-CT imaging experiment by using PC3 and H2009 (a lung cancer model) tumor-bearing mouse models. However due to the availability of 64 Cu and the tumor-growth rate difference between PC3 and H2009, the tumor sizes of PC3 and H2009 could not be ideally matched for this preliminary evaluation. The PC3 tumors were around 100 mm 3 at the time of PET-CT imaging, while the H2009 tumor size was in the range of 100 -300 mm 3 . As shown in Figure 4 , the PC3 tumors were clearly visualized with 64 Cu-DOTA-NHGR 11 at 1 h and 4 h p.i., while the H2009 tumors became invisible on PET images after 4 h p.i. The PET imaging quantification further confirmed that the absolute uptake of 64 Cu-DOTA-NHGR 11 in the PC3 tumors was significantly higher than in the H2009 tumors throughout the imaging study, indicating the desired imaging specificity of 64 Cu-DOTA-NHGR 11 . The slow clearance of 64 Cu-DOTA-NHGR 11 from the PC3 tumors likely reflects the fact that the radiotracer had been internalized into the tumor cells within 1 h p.i., while the significant clearance of 64 Cu-DOTA-NHGR 11 from the H2009 tumors probably indicates that the radiotracer could not be efficiently internalized into the lung cancer cells. Intriguingly, there are reports that the syndecan-1 expression is lost in lung cancer (6, 7) .
Part of the research progress has been published on two journal articles: (1,4,7-triazacyclononane-1,4,7-triacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) .
2. In the Amino Acids paper, we demonstrated the potential of using NHGR 11 to develop specific PET imaging probes for distant prostate cancer metastases by both in vitro and in vivo evaluations performed with FITC-NHGR11 and 64 Cu-DOTA-NHGR11. [2, 3] It has been demonstrated that creation of multimers of a targeting molecule on one scaffold can efficiently improve cell-specific binding affinity by several orders of magnitude. [3] As such, various approaches have been reported to exploit multivalent scaffolds for the construction of molecular imaging probes. [4] [5] [6] [7] [8] [9] [10] However, their chemistries are often complicated and become even more so when a bifunctional chelator (BFC) must be attached to a separately multimerized construct in order to introduce a metal radionuclide for nuclear imaging.
Reportable Outcomes
Herein we present an approach to take advantage of the pendent arms of the commonly used BFCs to build simplified but potentially versatile multivalent scaffolds for multimeric presentation of targeting molecules. This type of multivalent scaffold features a chelator that forms a stable and neutral complex with a radiometal and multiple functional groups for the anchoring of targeting molecules. If required by in vivo pharmacokinetics, poly(ethylene glycol) (PEG) chains can be introduced between the chelate and targeting moieties.
To test the rationale of our design, we use a cyclic RGD peptide (c(RGDyK), [5, 11] a well-validated a u b 3 integrin ligand, for the construction of a divalent PET imaging probe from a chelate known to have a high affinity for 64 Cu (CB-TE2 A, Scheme 1). The divalent probe is anticipated to have a prolonged biological half-life and enhanced specific binding and retention in tissues expressing the a u b 3 integrin.
The stability of the metal complex is of critical importance in the design of a metal radiopharmaceutical. CB-TE2A forms one of the most stable complexes with 64 Cu, [12] and the Cu II -CB-TE2A complex is more resistant to reductive metal loss than are other tetramacrocyclic complexes. [13] However, its stability with 64 Cu may be reduced when used as a BFC in which one of the carboxylate groups is converted to an amide for conjugation to a targeting molecule, [14] leading to a positive charge on the 64 Cu moiety. To avoid this potential problem, we choose a-bromoglutaric acid-1-tert-butyl ester-5-benzyl ester (3) for the alkylation of CB-cyclam, which allows selective deprotection of the carboxylate groups by two separate procedures to conjugate with c(RGDyK) through the peripheral carboxylates to afford H 2 1 and H 2 2, respectively. As such, the unique feature of CB-TE2A is preserved in the conjugates, in which the two inner carboxylates can form a neutral octahedral complex with 64 Cu II along with the four nitrogen atoms of the macrocycle.
To evaluate the anticipated multivalent effect, a recently reported CB-TE2A analogue [15] was also synthesized and coupled with c(RGDyK) to form a monovalent CB-TE2A-RGD conjugate (H 2 1) as a control for comparison. Scheme 2 shows the synthetic routes to H 2 1 and H 2 2. The multiple-step synthetic route involves three parts: 1) synthesis of orthogonally protected compounds 5 and 7; 2) formation of NHSactivated ester intermediates 6 and 9 after selective deprotection of the peripheral carboxylate groups (NHS = Nhydroxysuccinimide); and 3) conjugation of c(RGDyK) to the NHS esters followed by acid deprotection of the inner carboxylate groups to form the products H 2 1 and H 2 2. Alkylation of CB-cyclam by 3 was asynchronous at the two nonbridged nitrogen atoms, with the monoalkylation product 4 predominating at room temperature (35-55 % yield even in the presence of excess of 3). [15] In comparison, the dialkylated product 7 was only formed at elevated temperatures. At 50 8C using two equivalents of 3 to CB-cyclam, only 20-45 % of 7 was found, and it was always accompanied by the monoalkylation product. Although 7 was difficult to elute from silica gel using common organic solvents, a good separation was obtained by adding 5-10 % isopropyl amine in ethyl acetate. It is noteworthy that the debenzylation of the peripheral carboxylate groups catalyzed by 10 % Pd/C in a hydrogen atmosphere always resulted in formation of the corresponding esters if the reaction was carried out in an alcohol solvent. This finding is likely due to the "proton sponge" nature of the CB-cyclam core that induces transesterification during debenzylation. No clean debenzylization could be accomplished in either methanol or ethanol, even in the presence of formic acid as described in literature. [15] However, THF/H 2 O (1:1) successful circumvented this problem and afforded debenzylation products in quantitative yield. These were then activated by NHS and conjugated to c(RGDyK) in the presence of ten equivalents N,N-diisopropylethylamine (DIPEA Chromatographic results showed no release of 64 Cu from the conjugates over a period of 48 h. This high stability is attributed to the CB-TE2A moiety in the conjugates. The a u b 3 binding affinities of H 2 1 and H 2 2 were measured by a competitive cell-binding assay using U87MG cells in which 125 Iechistation was employed as a u b 3 -specific radioligand for competitive displacement. [5] The U87MG cell line was chosen because the a u b 3 integrin density on the cell surface was the highest among the solid tumor cell lines that have been assessed. [16] The IC 50 values of c(RGDyK), H 2 1, and H 2 2, which represent their concentrations required to displace 50 % of the 125 I-echistation bound on the U87MG cells, were determined to be 110, 139, and 35 nm, respectively (n = 5). The slightly decreased a u b 3 binding of H 2 1 as compared to c(RGDyK) indicates a minute impact of CB-TE2A on the binding of c(RGDyK) to the a u b 3 integrin. As anticipated, H 2 2 exhibited a strong divalent effect measured by the multivalent enhancement ratio (MVE) calculated by dividing the IC 50 value of H 2 1 by that of H 2 2 (MVE = 4). [6] The distance between the two RGD motifs in H 2 2 is greater than 25 bonds (including the lysine spacers), the minimum spacing length required to realize multivalent binding of RGD motifs to the a u b 3 integrin. [5] It is noteworthy that as a downstream effect of multivalent binding, oligomerization of cell-surface receptors could initiate cellular internalization events, which might further enhance the specific accumulation in the target tissues. [17] In vivo small-animal imaging studies were performed on a Siemens Inveon PET-CT multimodality system. Six SCID mice (6-7 weeks old) bearing PC-3 human prostate cancer xenografts in both front flanks (tumor size ca. 230 mg) were randomized into two groups (n = 3) for the evaluation of [ Owing to the fact that the a u b 3 integrin is also expressed in other tissues (e.g. liver, kidneys, stomach, intestines) in young mice, but to a lesser extent (personal communications [18] ), an elevated uptake was observed in those organs with (Figure 1 : 1 h blockade) in tumors after co-injection of c(RGDyK) at a dose of 10 mg kg À1 . The quantitative PET image data and post-PET biodistribution data are presented in Table 1 and Tables S1-S3 (see the Supporting Information for details).
The significantly greater uptake and prolonged signal intensity of [
64 Cu]2 in tumors reflects the advantages of the scaffolding design of H 2 2, which affords optimal in vivo kinetics in addition to the anticipated multivalent effects. It should be pointed out that there are two chiral centers in the pendent arms of Cu2, which should statistically give rise to three diastereomers (R/R, S/S, and a meso R/S), even though they could not be distinguished by the techniques used herein. While the purpose of this work is to demonstrate the feasibility of building multivalent imaging probes from a bifunctional chelator, an enantiopure isomer of 3 should be considered for future clinical applications of this type of multivalent scaffold. Used as a sample targeting molecule herein, c(RGDyK) can obviously be replaced with other targeting peptides or small organic molecules for imaging of various diseases or non-invasive cell-surface receptor mapping. In summary, we have demonstrated a divalent scaffolding design for targeted imaging probe development. Obviously this concept can be applied to the design of other multivalent scaffolds based on NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) . androgen ablation therapy in prostate cancer (Oyama et al. 2004 ); 16b-18 F-fluoro-5a-dihydrotesterone was employed to detect prostate cancer metastases and access androgen receptor expression in vivo (Larson et al. 2004) ; and radiolabeled peptides have been exploited for specific prostate cancer imaging by targeting specific surface markers or receptors (Rogers et al. 2003; Chen et al. 2004a, b; Schuhmacher et al. 2005; Yang et al. 2006; Zhang et al. 2006) . However, the role of PET in the diagnosis of prostate cancer, either localized diseases or distal metastases, has not been established (Beheshti et al. 2009; Bouchelouche et al. 2009 ). Prostate cancer metastases, especially in their early stage, display the dormant characteristics of prostate cancer with relatively small size as compared to metastases of other carcinomas, such as breast and lung cancer (Fogelman et al. 2005; Langsteger et al. 2006 ). This represents a great challenge in the non-invasive detection of prostate cancer and its metastases. As such, it is highly desirable to develop specific PET imaging probes based on different molecular mechanisms.
Cell permeable peptides (CPPs) known as delivery vehicles that can cross cell membranes have been extensively used for intracellular delivery of varieties of bioactive cargos (Bucci et al. 2000; Gratton et al. 2003) . Of the commonly used CPPs, arginine-rich CPPs including HIV-Tat peptides and oligoarginines have been reported with high internalization efficacy likely because their guanidine moiety can form divalent hydrogen-bonds with phosphates, sulfates, and carboxylates on cellular components (Rothbard et al. 2004; Sakai et al. 2005) . In an effort to deliver a therapeutic peptide sequence derived from the proline-rich domain of DOC-2/ DAB2 for prostate cancer treatment, we found out a polyarginine peptide (NH 2 GR 11 ) with an unexpectedly preferential uptake in several prostate cancer cell lines (Zhou et al. 2006) , which initiated the work presented in this paper. Two experiments were designed to verify whether the uptake preference is a unique feature of NH 2 GR 11 and whether it displays similar uptake specificity to prostate cancer in vivo. One was performed with three oligoarginines differing in the number of the repeating arginine units (n = 9, 11, and 13), which were labeled with a fluorescent dye (FITC: fluorescein isothiocyanate). NH 2 GR 11 was found with significantly higher uptake than NH 2 GR 9 and NH 2 GR 13 in four human prostate cancer cell lines and in both normal and prostate cancer-bearing mouse models. Subsequently, a comparative PET-CT imaging study using prostate and lung cancer xenograft mouse models was carried out to test the specificity of using NH 2 GR 11 to image prostate cancer in vivo when labeled with 64 Cu (t 1/2 = 12.7 h; b ? : 0.653 meV, 17.4%), a positron emitter. Our preliminary results demonstrate the potential of NH 2 GR 11 to be developed as a specific imaging probe for the detection of prostate cancer metastases.
Materials and methods
Chemical reagents and instrument
All chemicals were of reagent grade and used as received unless otherwise noted. FITC-NHGR 9 , FITC-NHGR 11 , FITC-NHGR 13 , and DOTA-NHGR 11 (DOTA: 1, 4, 7, 4, 7, MALDI-TOF mass spectra were collected on a Voyager-DE TM PRO Biospectrometry Workstation (Applied Biosystems, Foster City, CA). Small animal PET-CT imaging studies were performed on a Siemens Inveon PET-CT Multimodality System (Siemens Medical Solutions Inc., Knoxville, TN).
Cell culture and animal models
All the cell lines used in this work (LNCaP, PZ-HPV-7, DU145, PC3, and H2009) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Both LNCaP and PC3 cell lines were cultured in T-media (Invitrogen Corporation, Carlsbad, CA) supplemented with 5% FBS and 19 penicillin/streptomycin. PZ-HPV-7 (an immortalized normal prostate epithelial cell line) and DU145 cell lines were maintained in PrEGM medium (Lonza, Walkersville, MD) and RPMI1640 medium (ThermoFisher Scientific, US) supplemented with 10% FBS and 19 penicillin/streptomycin, respectively. The H2009, a non-small lung cancer, cell line was cultured in RPMI1640 medium supplemented with 5% FBS. All the cell lines were cultured at 37°C in an atmosphere of 5% CO 2 and passaged at 75% confluence.
All animal studies were performed in compliance with guidelines set by the UT Southwestern Institutional Animal Care and Use Committee. Male nu/nu nude mice (5-7 weeks of age) were purchased from Harlan (Indianapolis, IN), and male SCID mice (6-8 weeks of age) were purchased from the UT Southwestern mouse-breeding core (Wakeland Colony). To establish the PC3 tumor xenograft mouse model, PC3 cell suspension was mixed 1:1 with Matrigel (BD Biosciences, Bedford, MA) and then injected subcutaneously (2 9 10 6 cells per site, injection volume 100 lL) into both flanks of animals. For the H2009 tumor model, the cell suspension was injected subcutaneously (1 9 10 6 cells per site, injection volume 100 lL) into the back of both shoulders of SCID mice. After injection, the animals were monitored three times a week by general observations. Small PET-CT imaging was performed when the tumors become palpable.
In vitro cell uptake and subcellular localization To determine the uptake efficiency of CPPs, 1 9 10 4 cells per well were seeded in 12-well plates and allowed to grow for 24 h. Then a FITC-tagged CCP (5 lM) was added and incubated with cells for 30 min. After removal of the medium, the cells were treated with Tryphan Blue (0.4% w/v, Mediatech, Inc., Herndon, VA) to quench the extracellular fluorescence and washed three times with cold PBS. The cells were then lysed with Tris Buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100). The fluorescence intensity was measured by SpectraMax M5 (Molecular Devices, Sunnyvale, CA) with an excitation wavelength of 490 nm, an emission wavelength of 530 nm, and a cutoff wavelength of 515 nm. The protein concentration in each well was determined using a BCA protein assay kit (Pierce, Rockford, IL). The uptake efficiency of each CPP was determined by normalizing the fluorescence intensity with the protein concentration and the relative uptake was calculated as compared to that of FITC-NHGR 11 . To determine the subcellular localization of a CPP, after 30 min incubation, the cells were fixed with 4% paraformaldehyde in PBS buffer and then counterstained with 1 lg/mL DAPI (Sigma, St. Louis, MO). Each sample was examined under a fluorescence microscope.
Preparation of
64 Cu-DOTA-NHGR 11
To a 1.5 mL vial containing 10 lg DOTA-NHGR 11 in 200 lL of 0.4 M NH 4 OAc solution (pH 6.5), 2-3 mCi of 64 Cu in 0.1 M HCl was added. The reaction mixture was vortexed and then incubated at 37°C. After 30-min incubation, 5 lL of 5 mM diethylenetriaminepentaacetic acid (DTPA) was added and the reaction mixture was incubated at room temperature for 5 min. The separation of 64 Cu-DOTA-NHGR 11 from 64 Cu-DTPA was carried out by passing the reaction mixture through a light C-18 Sep-Pak cartridge. After three times of washings with PBS, the product was eluted with 80% ethanol solution. Radio-TLC analysis was performed on a Rita Star Radioisotope TLC Analyzer (Straubenhardt, Germany) to monitor the radiolabeling reaction using ITLC paper as the plate and 10 mM PBS as the mobile phase. High performance liquid chromatography (HPLC) analysis was conducted to determine the radiochemical purity of the products using a Waters 600 Multisolvent Delivery System equipped with a Waters 2996 Photodiode Array (PDA) detector and an in-line Shell Jr. 2000 radio-detector (Fredericksburg, VA) on a Waters Xterra column (150 9 4.6 mm, 5 lm). The mobile phase was H 2 O with 0.1% TFA (solvent A) and acetonitrile with 0.1% TFA (solvent B). The gradient was 5-20% B in 0-5 min and 20-40% B in 5-25 min at 1.0 mL/min flow rate.
The cold reference of nat Cu-DOTA-NHGR 11 was prepared by reacting 1 mg (0.46 lmol) of DOTA-NHGR 11 with 62 lg (0.46 lmol) of CuCl 2 in 1 mL of 0.4 M NH 4 OAc solution at 37°C for 1 h. The product was purified by HPLC using the same condition described above and characterized by MALDI-Mass (MALDI-TOF/MS: 2242.1 [M ? H ? ]). The fraction corresponding to nat Cu-DOTA-NHGR 11 was lyophilized and stored for use as cold standard.
Biodistribution and pharmacokinetic studies
The biodistribution studies were performed in control and PC3 tumor-bearing male nu/nu nude mice. Each mouse was injected intraperitoneally with a FITC-tagged CPP at a dose of 5 nmol/g of body weight. The animals were killed at 24 h post-injection (p.i.) and the organs of interest [prostate, seminal vesicle (SV), coagulation gland (CG), testis, liver, spleen, kidneys, muscle, lung, brain, and tumor] were excised, weighed, and measured by the fluorescence reader. The relative FITC intensity of each CPP was calculated as fluorescence intensity per gram of tissue weight.
Pharmacokinetic parameters were estimated by a twocompartment model using normal male nu/nu nude mice. Blood (*5 lL) was drawn from the retro-orbital sinus of the mice at 5, 10, 20, and 40 min after the tail vein injection of 64 Cu-DOTA-NHGR 11 , and then counted on a c-counter.
Small animal PET/CT imaging
When the tumor size reached the range of 50-300 mm 3 , the tumor-bearing mice were randomized for the PET-CT imaging with 64 Cu-DOTA-NHGR 11 . The injected dose was 3.7 MBq of 64 Cu-activity in 100 lL of PBS, while the injected molar amount of NH 2 GR 11 was maintained at the same level by decay correction.
Ten minutes prior to imaging, the animal was anesthetized using 3% isofluorane at room temperature until stable vitals were established. Once the animal was sedated, it was placed onto the imaging bed under 2% isofluorane anesthesia for the duration of the imaging. The CT imaging was acquired at 80 kV and 500 lA with a focal spot of 58 lm. The total rotation of the gantry was 360°with 360 rotation steps obtained at an exposure time of approximately 235 ms/frame. The images were attained using a CCD readout of 4,096 9 3,098 with a bin factor of 4 and an average frame of 1. Under low magnification, the effective pixel size was 103.03 lm. Total CT scan time was approximately 6 min. CT images were reconstructed with a down sample factor of 2 using Cobra Reconstruction Software. The PET imaging was performed directly after the acquisition of CT data. The PET tracer was injected intravenously via the tail vein. Static PET scans were performed at 1, 4, and 24 h p.i. for 15 min. PET images at 1, 4, and 24 h p.i. were reconstructed using Fourier Rebinning and Ordered Subsets Expectation Maximization 3D (OSEM3D) algorithm. Reconstructed CT and PET images were fused and analyzed using the Siemens Inveon Research Workplace (IRW) software. For quantification, regions of interest were placed in the areas expressing the highest radiotracer activity as determined by visual inspection. The tissues examined include the left and right tumors, heart, liver, lung, kidneys, and muscle. The resulting quantitative data were expressed as percent injected dose per gram of tissue (%ID/g).
Statistical analysis
Quantitative data were expressed as mean ± SD and then compared using one-way analysis of variance and Student's t test. P values \0.05 were considered statistically significant.
Results
In vitro cell uptake and subcellular localization
The oligoarginine length effect on the cell uptake efficiency was evaluated using FITC-NHGR 9 , FITC-NHGR 11 and FITC-NHGR 13 in four different human prostate cell lines: PZ-HPV-7, LNCaP, PC3, and DU145. For comparison, the uptake of FITC-NHGR 11 in LNCaP is set at 1.0. As shown in Fig. 1a than FITC-NHGR 9 and FITC-NHGR 13 (P \ 0.005) in all the four cell lines indicating that the intracellular uptake of oligoarginines is greatly affected by the number of the repeating guanidino moiety. Of the three FITC-tagged oligoarginines, FITC-NHGR 13 showed the lowest uptake in three of the tested cell lines PC3, and DU145) . In PC3 and DU145, FITC-NHGR 9 displayed appreciable uptake values, which are 63 and 65% of that of FITC-NHGR 11 , respectively. Overall, the PZ-HPV-7 and LNCaP cell lines exhibited highly selective internalization of oligoarginines varying with the peptide length. The subcellular localization of FITC-NHGR 9 , FITC-NHGR 11 , in the prostate cancer cell lines was shown in Fig. 1b . Apparently, FITC-NHGR 11 exhibited a higher fluorescent intensity in all the cell lines. The majority of FITC-NHGR 11 was localized in the cytosol, while in PZ-HPV-7 and PC3 cell lines, nuclear staining with FITC-NHGR 11 was also seen. Both FITC-NHGR 9 and FITC-NHGR 13 showed significantly lower fluorescent intensity than FITC-NHGR 11 in all four tested cell lines, which is consistent with the cell uptake results. Taken together, these data demonstrate the high efficiency and amino acid length-dependent uptake of FITC-NHGR 11 in various prostate cell lines, which has made FITC-NHGR 11 as a unique probe for detecting prostate cancer.
Preparation of
To label NH 2 GR 11 with 64 Cu, a commonly used bifunctional chelator, DOTA was conjugated to the N terminus of the peptide. The conjugate, DOTA-NHGR 11 , was labeled with 64 Cu by incubating with 64 Cu 2? in 0.4 M NH 4 OAc buffer (pH 6.5) at 37°C for 30 min. Non-specifically bound 64 Cu was removed in the form of 64 Cu-DTPA at the end of the radiolabling procedure. The radiolabeling reaction was monitored by radio-TLC analysis, in which the reaction mixture was sampled on an instant TLC plate that was then developed in PBS buffer. Under the TLC conditions, 64 Cu-DOTA-NHGR 11 stayed at the origin, while 64 Cu-DTPA moved to the solvent front. The radiochemical yield was [90% when 10 lg of the DOTA conjugate was used to label 2-3 mCi of 64 Cu. The 64 Cu-DTPA was removed by passing the reaction mixture through a light C18 Sep-Pak cartridge and three times of washing with PBS. The product, 64 Cu-DOTA-NHGR 11 , could then be efficiently eluted with 80% of ethanol. The radiochemical purity of 64 Cu-DOTA-NHGR 11 was nearly 100% after the Sep-Pak purification as determined by radio-ITLC and radio-HPLC.
To confirm the identity of the labeled product, nat Cu-DOTA-NHGR 11 was prepared and used as a reference standard. Both 64 Cu-DOTA-NHGR 11 and nat Cu-DOTA-NHGR 11 showed a single peak on HPLC ( 64 Cu-DOTA-NHGR 11 : radioactivity detector;
nat Cu-DOTA-NHGR 11 :
PDA UV detector) with the same retention time within 14-15 min.
Biodistribution and in vivo pharmacokinetics
The tissue distribution of FITC-NHGR 9 , FITC-NHGR 11 , and FITC-NHGR 13 was conducted in control and PC-3 tumor-bearing nude mice. The biodistribution data are presented in Figs. 2 and 3 , respectively. For comparison, the uptake value of FITC-NHGR 9 in the prostate is set at 1.0 in Fig. 2 . Compared to FITC-NHGR 9 and FITC-NHGR 13 , FITC-NHGR 11 clearly showed preferential accumulation in the prostate tissue as measured by the uptake ratios of the prostate to other organs. As shown in Fig. 3 , FITC-NHGR 11 displayed high relative uptake values in both prostate tissue and prostate tumor. Impressively, the uptake ratios of tumor to muscle and prostate to muscle were 3.8 and 8.7, respectively. In addition, showed low uptake in the major clearance organs (e.g. liver, spleen, and kidneys).
Given the limited capability of fluorescence imaging quantification for in vivo evaluations, the in vivo pharmacokinetics of NH 2 GR 11 was evaluated using 64 Cu-DOTA-NHGR 11 in normal mice based on a two-compartment model. Its half-life in the blood (the primary compartment) was 10.7 min; and the elimination half-life from other organs (the secondary compartment) was 17.2 h.
Small animal PET-CT imaging
The comparative small animal imaging evaluation of 64 Cu-DOTA-NHGR 11 was performed using PC3 and H2009 tumor-bearing SCID mice, which were injected with a Fig. 4 . Clearly the PC3 tumors on both flanks were visualized by 64 Cu-DOTA-NHGR 11 on PET images at 1, 4 and 24 h p.i. In contrast, the H2009 tumors were only visible at 1 and 4 h with much lower signal intensity on PET as compared to the PC3 tumors; at 24 h p.i., they became not detectable.
The PET images were quantitatively analyzed by the Siemens Inveon Research Workplace (IRW) software. Summarized in Table 1 are the uptake values of 64 Cu-DOTA-NHGR 11 in the regions of interest [tumors (left and right), heart, liver, lung, kidney (left), and muscle] obtained from the imaging quantification. Not surprisingly, 64 Cu-DOTA-NHGR 11 showed nearly identical uptake values in the right and left tumors. The accumulation level of 64 Cu-DOTA-NHGR 11 in the PC3 tumors remained steady out to 24 h p.i. (1.17 ± 0.19%ID/g at 1 h p.i.; 0.91 ± 0.32%ID/g at 4 h; 24 h 0.82 ± 0.24%ID/g at 24 h), whereas its uptake in the H2009 tumors was significantly lower (P \ 0.02) and showed an appreciable trend of decreases over time (0.81 ± 0.07%ID/g at 1 h p.i.; 0.47 ± 0.12%ID/g at 4 h; 24 h 0.33 ± 0.05%ID/g at 24 h). Impressively, the uptake ratios of 64 Cu-DOTA-NHGR 11 in PC3 tumor versus muscle at 1, 4, and 24 h p.i. were 5.06 ± 0.96, 4.87 ± 1.29, and 10.41 ± 6.07, respectively. In other organs, 64 Cu-DOTA-NHGR 11 exhibited a very similar distribution pattern in both tumor-bearing mouse models.
Discussion
In spite of the extensive utilization of arginine-rich CPPs for intracellular delivery of a broad range of bioactive materials, the internalization mechanisms of CPPs are still under investigation. It has been reported that a slight structural alteration might lead to significant changes of the CPP internalization mechanisms or subcellular localization, which can thereby considerably affect its internalization efficiency and the bioavailability of its cargos (Nakase et al. 2008) . Internalization selectivity of CPPs into specific cells or organs is highly desirable for efficient target delivery of therapeutics in order to minimize the side effects on non-target organs. This selectivity can be obviously imparted by attaching a targeting molecule to the CPP-cargo conjugate, although it adds complexity to the overall construct. From screening of various CPPs for the potential candidate of delivery vehicle in prostate cancer, we have reported that an arginine-rich CPP exhibits a high efficiency of intracellular uptake in vitro (Zhou et al. 2006) . In 2007, Elson-Schwab et al. (2007) reported that the delivery of arginine-rich CPPs at nanomolar transporter concentrations was completely mediated by the membraneassociated heparan sulfate proteoglycans (HSPG). Given the fact that the expression level of HSPG varies with cell type (Sasisekharan et al. 2002; Sanderson et al. 2004) , it is not surprising that CPPs with certain structure or sequence may display cell or organ specificity to some extent. Indeed, the fact that the negatively charged heparan sulfates on HSPG can form divalent hydrogen-bonds with the guanidino groups (Nakase et al. 2008 ) may explain the role of HSPG in the internalization of arginine-rich CPPs.
Heparan sulfate proteoglycans consist of a diverse family of glycosaminoglycan-bearing protein cores including the syndecans and perlecan (Kirn-Safran et al. 2009 ). Recently, Datta et al. (2006) reported that perlecan, also called HSPG-2, is highly expressed in various prostate cancer cell lines including LNCaP, PC3, and DU145, and the cell growth is inhibited by silencing the expression of perlecan. In addition, the level of perlecan in prostate cancer tissues was found in good correlation with the Gleason score and rapid cell proliferation. Similarly, syndecan-1, a cell membrane-bound HSPG, was reported with a great overexpression during the androgen-independent progression of prostate cancer in a mouse model (Alexander et al. 2000) and the androgen-independent prostate cancer cell lines, such as PC3 and DU145 (Chen et al. 2004a, b) .
The preferential uptake of NH 2 GR 11 that we observed in various prostate cancer cell lines could be reasonably explained by the upregulated expression of HSPG in prostate tissues or cancer cells. This prompted us to speculate the potential application of NH 2 GR 11 as PET imaging probe for the diagnosis of prostate cancer, while the detailed mechanism of this specific uptake may take years of research to reveal. It is noteworthy that other CPPs with different sequences or lengths may exhibit similar or even better prostate tissue uptake specificity. Given the high uptake of NH 2 GR 11 was also observed in the normal prostate tissue (Figs. 2, 3) , we believe that the NH 2 GR 11 -based PET imaging probes will be more suitable for the detection of distant prostate cancer metastases such as lymph node and bone metastases rather than primary prostate tumor. Indeed, there has been a postulation that the bone extracellular matrix is a perlecan-rich site, which explains why prostate cancer preferentially metastasizes to the bone (Datta et al. 2006) .
In the present work, we first evaluated the length effect on the internalization efficiency using three FITC-tagged oligoarginines differing in the number of repeating arginine units in hope for an optimal length for the following evaluations. The in vitro cell uptake and subcellular localization experiments were performed in four different prostate cell lines. The result was what we anticipated to some extent. The CPP with 11 arginine-repeating units, NH 2 GR 11 , unequivocally demonstrated its superiority over other two CPPs with either shorter or longer length in term of absolute cell uptake and internalization efficiency (Fig. 1) . As shown in Fig. 1b , NH 2 GR 11 was primarily presented in the cytosol after being internalized.
Given the in vitro result, we proceeded to evaluate whether NH 2 GR 11 could maintain the superior properties in normal nude mice as compared to NH 2 GR 9 and NH 2 GR 13 . As measured by the uptake ratios of the prostate to other organs, a clear preferential accumulation in the prostate tissue was observed for FITC-NHGR 11 but not for either FITC-NHGR 9 or FITC-NHGR 13 . This overall in vivo uptake result of the three FITC-tagged peptides is similar to the in vitro result, indicating that the biologic activity of these CPPs remains quite consistent under the environment of different tissue types. Nevertheless, this high uptake in normal prostate tissue exhibited by FITC-NHGR 11 precludes NH 2 GR 11 from being considered as imaging probes for primary prostate cancer detection. However, it can be well suited for the detection of distant prostate cancer metastases. As such we further evaluated the biodistribution profile of FITC-NHGR 11 in PC3 tumorbearing animal with the tumor distant from the normal prostate (Fig. 3) . In addition to the expected high uptake in the prostate, FITC-NHGR 11 showed elevated accumulation in the PC3 tumor, which serves as an analogic model of distant prostate cancer metastasis.
The in vivo pharmacokinetics of NH 2 GR 11 evaluated with 64 Cu-DOTA-NHGR 11 in normal mice showed that the CPP was cleared from the blood rapidly with a half-life of 10.7 min, but its elimination half-life from other organs Data are presented as %ID/g ± SD (n = 3; *P \ 0.02; **P \ 0.002; ***P \ 0.001) (the secondary compartment) was rather long (17.2 h The labeling of DOTA-NHGR 11 with 64 Cu was straightforward. The radiochemical yields were reasonably high. After the purification by a light C18 Sep-Pak cartridge, the radiochemical purity of 64 Cu-DOTA-NHGR 11 was nearly 100% as determined by a reverse phase HPLC method. The specific radioactivity of 64 Cu-DOTA-NHGR 11 was 11 GBq/lmol.
With the goal to develop NH 2 GR 11 for specific PET imaging of prostate cancer metastases, we designed and performed a comparative PET-CT imaging experiment using PC3 and H2009 tumor-bearing mouse models. However, due to the availability of 64 Cu and the tumorgrowth rate difference between PC3 and H2009, the tumor sizes of PC3 and H2009 could not be ideally matched for this preliminary evaluation. The PC3 tumors were around 100 mm 3 at the time of PET-CT imaging, while the H2009 tumor size was in the range of 100-300 mm 3 . However, the PC3 tumors were clearly visualized with 64 Cu-DOTA-NHGR 11 at 1, 4, and 24 h p.i., while the H2009 tumors became invisible on PET images after 4 h p.i. The PET imaging quantification further confirmed that the absolute uptake of 64 Cu-DOTA-NHGR 11 in the PC3 tumors was significantly higher than in the H2009 tumors throughout the imaging study, indicating the desired imaging specificity of 64 Cu-DOTA-NHGR 11 . The slow clearance of 64 Cu-DOTA-NHGR 11 from the PC3 tumors likely reflects the fact that the radiotracer had been internalized into the tumor cells within 1 h p.i., while the significant clearance of 64 Cu-DOTA-NHGR 11 from the H2009 tumors probably indicates that the radiotracer could not be efficiently internalized into the lung cancer cells. Intriguingly, there are reports that the syndecan-1 expression is lost in lung cancer (Nackaerts et al. 1997; Chen et al. 2004a, b) .
It is noteworthy that the biodistribution profiles of NH 2 GR 11 obtained from FITC-NHGR 11 and 64 Cu-DOTA-NHGR 11 ( Fig. 2; Table 1 ) are not in good agreement with regard to the uptake values in the liver and kidneys. While the discrepancies might be caused by the different administration routes of FITC-NHGR 11 and 64 Cu-DOTA-NHGR 11 , the high accumulation of 64 Cu-DOTA-NHGR 11 in the liver could be partially resulted from the dislocation of 64 Cu from the DOTA moiety (Boswell et al. 2004 ). To circumvent this in vivo stability problem, in our future evaluations of NH 2 GR 11 , we will replace the DOTA moiety with a cross-bridged tetraazamacrocyclic bifunctional chelator (CB-TE2A: 4,11-bis(carboxymethyl) -1,4,8,11-tetraazabicyclo[6.6.2] hexadecane) whose 64 Cu-complex has been shown with strong resistance to the in vivo transchelation of 64 Cu .
Conclusions
We have demonstrated the potential of using NHGR 11 to develop specific PET imaging probes for distant prostate cancer metastases by both in vitro and in vivo evaluations performed with FITC-NHGR 11 and 64 Cu-DOTA-NHGR 11 . Further mechanistic elucidation of the cell uptake and internalization of arginine-rich CPPs would facilitate the development of this unique group of molecules for targeted molecular imaging and drug delivery.
